Research Article
Postchemoradiotherapy Neutrophil-to-Lymphocyte Ratio Predicts Distant Metastasis and Survival Results in Locally Advanced Pancreatic Cancers
Table 1
Baseline patient and disease characteristics.
| | Characteristics | All patients (N = 126) | NLR <3.1 (N = 62) | NLR ≥3.1 (N = 64) | value |
| | Median age, years (range) | 58 (26–79) | 59 (26–79) | 57 (34–78) | 0.92 | | Age groups, N (%) | | | | 0.81 | | <70 | 92 (73.0) | 45 (72.6) | 47 (73.4) | | ≥70 | 34 (27.0) | 17 (27.4) | 17 (26.6) | | Gender, N (%) | | | | 0.79 | | Female | 29 (23.0) | 14 (22.6) | 15 (23.4) | | Male | 97 (77.0) | 48 (774) | 49(76.6) | | ECOG performance, N (%) | | | | 0.42 | | 0 | 41 (32.5) | 21 (33.9) | 20 (31.3) | | 1 | 85 (67.5) | 41 (66.1) | 44 (68.7) | | Tumor location, N (%) | | | | 0.76 | | Head | 94 (74.6) | 45 (72.6) | 49 (76.6) | | Body/tail | 32 (25.4) | 17 (37.4) | 15 (23.4) | | Median tumor size, mm (range) | 37 (26–79) | 35 (26–74) | 39 (28–79) | 0.28 | | Tumor size group, N (%) | | | | 0.19 | | <37 mm | 60 (47.6) | 32 (51.6) | 28 (43.8) | | ≥37 mm | 66 (52.4) | 30 (48.4) | 36 (56.2) | | N-stage, N (%) | | | | 0.23 | | 0 | 61 (48.4) | 32 (51.6) | 29 (45.3) | | 1–2 | 65 (51.6) | 30 (48.4) | 35 (54.7) | | CA 19–9, N (%) | | | | 0.002 | | ≤90 U/m/L | 54 (42.9) | 33 (53.2) | 21 (32.8) | | >90U/m/L | 72 (57.1) | 29 (46.8) | 43 (67.2) | | Median pre-CCRT NLR | 2.71 (1.5–5.7) | 2.18 (1.5–4.1) | 3.54 (2.3–5.7) | 0.0014) |
|
|
Abbreviations. NLR: neutrophil-to-lymphocyte ratio; ECOG: Eastern Cooperative Oncology Group; N-stage: nodal stage; CA 19–9: cancer antigen 19–9; CCRT: concurrent chemoradiotherapy.
|
